...
首页> 外文期刊>Journal of refractive surgery >Anterior subcapsular opacities and cataracts 5 years after surgery in the visian implantable collamer lens FDA trial.
【24h】

Anterior subcapsular opacities and cataracts 5 years after surgery in the visian implantable collamer lens FDA trial.

机译:在visian植入式散光镜FDA试验中,术后5年内前囊膜混浊和白内障。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To use the techniques of survival analysis to analyze the incidence of anterior subcapsular opacities (symptomatic and asymptomatic) and clinically significant cataract in the US Food and Drug Administration clinical trial of the Visian Implantable Collamer Lens (ICL). METHODS: Five hundred twenty-six eyes were followed for an average of 4.7 years; 89% (468 eyes), 73% (384 eyes), and 59% (311 eyes) were seen at 3, 4, and 5 years or later, respectively. Anterior subcapsular opacities were defined as trace or more (> or =0.6 LOCS III opacity). Clinically significant cataract required loss of 2 or more lines of best spectacle-corrected visual acuity (BSCVA), a significant increase in glare symptoms, or cataract extraction. Kaplan-Meier analyses of opacities and cataract were performed. RESULTS: The Kaplan-Meier cumulative probability estimate for anterior subcapsular opacities over 7+ years of follow-up was 7% whereas 31 (5.9%) eyes were actually observed. Anterior subcapsular opacities generallyoccurred early with 58% seen in the first year, 68% in the first 2 years, and 74% in the first 3 years. The cumulative probability estimate for clinically significant cataracts over the 7+ years of follow-up was 2% whereas 7 (1.3%) were actually observed. The difference between the Kaplan-Meier estimate and the actual observed percentage is due to the fact that the former takes into account the differences in postoperative follow-up time of individual eyes. Preoperative myopia (>12.00 diopters) and patient age (>40 years) were significant factors in the development of cataract. No loss of BSCVA was observed in any eye following cataract extraction. CONCLUSIONS: Approximately 6% to 7% of eyes develop anterior subcapsular opacities at 7+ years following ICL implantation but only 1% to 2% progress to clinically significant cataract during the same period, especially very high myopes and older patients. Visual outcome following cataract extraction was good.
机译:目的:使用生存分析技术来分析美国食品药品监督管理局(Visian Implantable Collamer Lens,ICL)的临床试验中前囊膜混浊(有症状和无症状)和具有临床意义的白内障的发生率。方法:对526只眼进行了平均4。7年的随访。在3年,4年和5年或更晚的时间分别看到89%(468眼),73%(384眼)和59%(311眼)。前囊膜混浊定义为痕量或更多(>或= 0.6 LOCS III混浊)。临床上重要的白内障需要损失2或更多行最佳眼镜矫正视力(BSCVA),眩光症状显着增加或白内障摘除。进行了不透明度和白内障的Kaplan-Meier分析。结果:在7年以上的随访中,前囊膜混浊的Kaplan-Meier累积概率估计为7%,而实际观察到31眼(5.9%)。前囊膜混浊通常较早发生,第一年出现58%,头两年出现68%,头三年出现74%。在7年以上的随访中,具有临床意义的白内障的累积概率估计为2%,而实际观察到7例(1.3%)。 Kaplan-Meier估计值与实际观察到的百分比之间的差异是由于前者考虑了各个眼睛术后随访时间的差异。术前近视(> 12.00屈光度)和患者年龄(> 40岁)是白内障发展的重要因素。白内障摘除后任何一只眼睛都没有观察到BSCVA的损失。结论:ICL植入后7年以上,约有6%至7%的眼睛发展为前囊膜混浊,但在同一时期,只有1%至2%的患者发展为具有临床意义的白内障,特别是高度近视和老年患者。白内障摘除术后视觉效果良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号